Pierre A. Van Damme
Advanced in Cervical Cancer

Pierre A. Van Damme

Antwerpen, VLG, BE 
Advanced in Cervical Cancer
Antwerpen, VLG, BE 
OverviewLocationsClinical Research

Overview

Pierre Van Damme practices in Antwerpen, Belgium. Mr. Van Damme is rated as an Advanced expert by MediFind in the treatment of Cervical Cancer. His top areas of expertise are Pertussis, Hepatitis A, Tetanus, and Human Papillomavirus Infection.

His clinical research consists of co-authoring 278 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 17 articles in the study of Cervical Cancer.

Gender
Male

Locations

Antwerpen, VLG, Belgium
Other Locations
Wilrijk, VLG, Belgium
Edegem, VLG, Belgium
Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase
A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological, Other
Study Phase: Phase 1
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
Enrollment Status: Completed
Publish Date: March 06, 2023
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years.
Enrollment Status: Completed
Publish Date: September 22, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Developing Methods to Investigate Additional Opportunities of HPV Vaccination, Including Control of Infection and Transmission, by Using a Cervicovaginal Human Sample, Collected by Urination (HPV-VACPLUS)
Developing Methods to Investigate Additional Opportunities of HPV Vaccination, Including Control of Infection and Transmission, by Using a Cervicovaginal Human Sample, Collected by Urination (HPV-VACPLUS)
Enrollment Status: Completed
Publish Date: September 29, 2021
Intervention Type: Other
Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders
Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders
Enrollment Status: Completed
Publish Date: January 31, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

278 Total Publications

The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birth.
The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birth.
Journal: Human vaccines & immunotherapeutics
Published: December 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Damme's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile